Amneal Pharmaceuticals, Zambob's Parkinson's Treatment Recommended by European Committee for Approval

MT Newswires Live06-29

Amneal Pharmaceuticals (AMRX) and Zambon's therapy Hopledo has received a positive opinion by the Committee for Medicinal Products for Human Use recommending European Medicines Agency marketing authorization for the treatment of adult patients with Parkinson's disease and moderate to severe motor fluctuations, the companies said Monday.

The specific indication is for those patients who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatments, the companies said

The recommendation was based on data from a 506-patient phase 3 in which Hopledo showed a "significant" improvement over immediate-release levodopa/carbidopa with fewer daily doses and with a comparable safety profile, the companies said.

If approved, the companies expect to make Hopledo available beginning in October, the companies said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647324588?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 16:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647324588","market":"us","top_or_hot":-1,"title":"Amneal Pharmaceuticals, Zambob's Parkinson's Treatment Recommended by European Committee for Approval","media":"MT Newswires Live","content":"<html><body><p> Amneal Pharmaceuticals (AMRX) and Zambon's therapy Hopledo has received a positive opinion by the Committee for Medicinal Products for Human Use recommending European Medicines Agency marketing authorization for the treatment of adult patients with Parkinson's disease and moderate to severe motor fluctuations, the companies said Monday.</p><p>The specific indication is for those patients who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatments, the companies said</p><p>The recommendation was based on data from a 506-patient phase 3 in which Hopledo showed a \"significant\" improvement over immediate-release levodopa/carbidopa with fewer daily doses and with a comparable safety profile, the companies said.</p><p>If approved, the companies expect to make Hopledo available beginning in October, the companies said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amneal Pharmaceuticals, Zambob's Parkinson's Treatment Recommended by European Committee for Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmneal Pharmaceuticals, Zambob's Parkinson's Treatment Recommended by European Committee for Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-29 16:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Amneal Pharmaceuticals (AMRX) and Zambon's therapy Hopledo has received a positive opinion by the Committee for Medicinal Products for Human Use recommending European Medicines Agency marketing authorization for the treatment of adult patients with Parkinson's disease and moderate to severe motor fluctuations, the companies said Monday.</p><p>The specific indication is for those patients who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatments, the companies said</p><p>The recommendation was based on data from a 506-patient phase 3 in which Hopledo showed a \"significant\" improvement over immediate-release levodopa/carbidopa with fewer daily doses and with a comparable safety profile, the companies said.</p><p>If approved, the companies expect to make Hopledo available beginning in October, the companies said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPV","symbol_name":"ProShares UltraShort MSCI Europe","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647324588","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647324588","pubTimestamp":1782721557,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amneal Pharmaceuticals  and Zambon's therapy Hopledo has received a positive opinion by the Committee for Medicinal Products for Human Use recommending European Medicines Agency marketing authorization for the treatment of adult patients with Parkinson's disease and moderate to severe motor fluctuations, the companies said Monday.The specific indication is for those patients who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatments, the companies saidThe recommendation was based on data from a 506-patient phase 3 in which Hopledo showed a \"significant\" improvement over immediate-release levodopa/carbidopa with fewer daily doses and with a comparable safety profile, the companies said.If approved, the companies expect to make Hopledo available beginning in October, the companies said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EPV":"ProShares UltraShort MSCI Europe","BK4007":"制药","AMRX":"Amneal Pharmaceuticals, Inc."},"translate_title":"Amneal Pharmaceuticals，Zambob治疗帕金森获欧盟委员会推荐批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPV":1.5,"AMRX":1},"content_text":"Amneal Pharmaceuticals (AMRX) and Zambon's therapy Hopledo has received a positive opinion by the Committee for Medicinal Products for Human Use recommending European Medicines Agency marketing authorization for the treatment of adult patients with Parkinson's disease and moderate to severe motor fluctuations, the companies said Monday.The specific indication is for those patients who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatments, the companies saidThe recommendation was based on data from a 506-patient phase 3 in which Hopledo showed a \"significant\" improvement over immediate-release levodopa/carbidopa with fewer daily doses and with a comparable safety profile, the companies said.If approved, the companies expect to make Hopledo available beginning in October, the companies said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647324588","isCrawlerRequest":true}